US Stock MarketDetailed Quotes

CRDF Cardiff Oncology

  • 2.510
  • 0.0000.00%
Close Jul 15 16:00 ET
  • 2.500
  • -0.010-0.40%
Post 19:33 ET
112.29MMarket Cap-2788P/E (TTM)

About Cardiff Oncology Company

Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. The firm's clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.

Company Profile

Company NameCardiff Oncology
Listing DateJul 31, 2003
CEODr. Mark Erlander, PhD
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address11055 Flintkote Avenue
CitySan Diego
CountryUnited States of America
Zip Code92121

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Mark Erlander, PhD
  • Director and Chief Executive Officer
  • 1.55M
  • James E. Levine
  • Chief Financial Officer and Principal Accounting Officer
  • 917.72K
  • Dr. Fairooz Kabbinavar, M.D.
  • Chief Medical Officer
  • 1.26M
  • Dr. Rodney S. Markin,M.D.,PhD
  • Chairman of the Board
  • 154.43K
  • Lale White
  • Independent Director
  • 116.43K
  • Dr. Renee P. Tannenbaum, D.Pharm.
  • Independent Director
  • 110.43K
  • Dr. Mani Mohindru, PhD
  • Independent Director
  • 112.43K
  • Dr. James O. Armitage,M.D.
  • Independent Director
  • 104.43K
  • Dr. Gary W. Pace,PhD
  • Independent Director
  • 114.43K


Analyst Rating

No Data

Price Target

No Data

Heat List
Latest Price